Market Overview

The EU Ovarian Cancer Diagnostics and Therapeutics Market was valued at XX Million US$ in 2019 and is projected to reach XX Million US$ by 2028, at a CAGR of 8.7% during the forecast period

A cancer that begins in the female organs that produce eggs (ovaries). Ovarian cancer often goes undetected until it has spread within the pelvis and stomach. At this late stage, ovarian cancer is more difficult to treat and can be fatal. Ovarian cancer often has no symptoms in the early stages. Later stages are associated with symptoms, but they can be non-specific, such as loss of appetite and weight loss. Surgery and chemotherapy are generally used to treat ovarian cancer. The incidences of ovarian cancer are high in women, who are aged between 55-64 years. As per Cancer Research UK, ovarian cancer is the fifth most common cancer in the EU for females. Moreover, as per Globocan estimates, the EU recorded 67,771 new ovarian cancer cases in 2018, with 44,576 deaths. With the rising burden of cancer, there is a need for effective treatment. Hence, owing to these factors, the market is expected to witness significant growth over the forecast period